Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB104 pharmacodynamic effects on brain circuitry in healthy participants
NCT04068532Phase 1Completed
- Sponsor
- Biogen
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Placebo with BIIB104 (2 arms). Primary endpoint: Change From Baseline in Faces Versus Shapes Emotional Faces Task Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Contrasts at Day 4. Started Nov 2019; status: completed.
02
Drugs
pesampator
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04068532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068532.